Analytical Data
-
基因名
CRTAM/CD355
- Application
-
别名
Cytotoxic and Regulatory T-Cell Molecule; Class-I MHC-Restricted T-Cell-Associated Molecule; CD355; CRTAM
-
种属
Human
-
表达系统
HEK293
-
标签
C- His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
O95727
-
表达区间
18-286aa
-
分子量
30.99 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CRTAM (Cytokine Response Modifier A) is a type I membrane protein that plays a critical role in immune responses and is primarily expressed in T cells, NK cells, and some other immune cells. It is known to be involved in the regulation of T cell activation and the modulation of immune responses, especially in the context of tumor immunity and viral infections. The CD355 designation refers to its identification in the CD antigen classification system. Research has indicated that CRTAM can influence the activation of cytotoxic lymphocytes, thereby enhancing their ability to target and eliminate tumor cells. Its importance in immunological contexts has prompted investigations into its potential as a therapeutic target in cancer treatments and vaccines. Studies exploring recombinant forms of CRTAM/CD355 focus on elucidating the protein's structural and functional properties, understanding its interactions with other immune modulators, and assessing its efficacy in promoting anti-tumor immunity. Furthermore, given the rising interest in harnessing the immune system for cancer therapy, CRTAM/CD355 represents a promising avenue for developing innovative immunotherapeutic strategies.
